Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Spatial and temporal roles of SARS-CoV PL pro -A snapshot.

Tytuł:
Spatial and temporal roles of SARS-CoV PL -A snapshot.
Autorzy:
Yan S; National Engineering Research Center for Non-Food Biorefinery, State Key Laboratory of Non-Food Biomass and Enzyme Technology, Guangxi Biomass Engineering Technology Research Center, Guangxi Key Laboratory of Bio-Refinery, Guangxi Academy of Sciences, Nanning, China.
Wu G; National Engineering Research Center for Non-Food Biorefinery, State Key Laboratory of Non-Food Biomass and Enzyme Technology, Guangxi Biomass Engineering Technology Research Center, Guangxi Key Laboratory of Bio-Refinery, Guangxi Academy of Sciences, Nanning, China.
Źródło:
FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2021 Jan; Vol. 35 (1), pp. e21197.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
Język:
English
Imprint Name(s):
Publication: 2020- : [Bethesda, Md.] : Hoboken, NJ : Federation of American Societies for Experimental Biology ; Wiley
Original Publication: [Bethesda, Md.] : The Federation, [c1987-
MeSH Terms:
COVID-19/*virology
Coronavirus Papain-Like Proteases/*physiology
Severe acute respiratory syndrome-related coronavirus/*physiology
SARS-CoV-2/*physiology
Severe Acute Respiratory Syndrome/*virology
COVID-19/immunology ; COVID-19/therapy ; Coronavirus Papain-Like Proteases/genetics ; Genes, Viral ; Host-Pathogen Interactions ; Humans ; Molecular Targeted Therapy ; NF-kappa B/metabolism ; Protein Domains ; Protein Processing, Post-Translational ; Severe acute respiratory syndrome-related coronavirus/genetics ; SARS-CoV-2/genetics ; Severe Acute Respiratory Syndrome/immunology ; Severe Acute Respiratory Syndrome/therapy ; Substrate Specificity ; Ubiquitin-Activating Enzymes/metabolism ; Ubiquitin-Conjugating Enzymes/metabolism ; Ubiquitin-Protein Ligases/metabolism ; Ubiquitination ; Viral Proteins/metabolism ; Virus Replication
References:
Int J Mol Sci. 2016 May 05;17(5):. (PMID: 27164085)
J Invest Dermatol. 2013 May;133(5):1178-87. (PMID: 23235527)
Cells. 2014 May 06;3(2):386-417. (PMID: 24805990)
J Virol. 2004 Dec;78(24):13600-12. (PMID: 15564471)
Biochemistry. 2005 Aug 2;44(30):10349-59. (PMID: 16042412)
J Biol Chem. 2011 Oct 14;286(41):35388-95. (PMID: 21852228)
J Virol. 2005 Dec;79(24):15199-208. (PMID: 16306591)
Nat Rev Immunol. 2011 Dec 09;12(1):35-48. (PMID: 22158412)
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5192-201. (PMID: 27519799)
Cell. 2002 Dec 27;111(7):1041-54. (PMID: 12507430)
Virology. 1993 Aug;195(2):680-91. (PMID: 8337838)
FEBS J. 2014 Sep;281(18):4085-96. (PMID: 25039866)
EMBO J. 1987 Dec 1;6(12):3779-85. (PMID: 3428275)
PLoS Pathog. 2014 May 22;10(5):e1004113. (PMID: 24854014)
Protein Cell. 2010 Jan;1(1):59-74. (PMID: 21203998)
Virology. 1997 Apr 14;230(2):309-22. (PMID: 9143287)
FASEB J. 2021 Jan;35(1):e21197. (PMID: 33368679)
J Virol. 2005 Apr;79(7):4550-1. (PMID: 15767458)
J Mol Biol. 2003 Aug 29;331(5):991-1004. (PMID: 12927536)
Nat Rev Microbiol. 2008 Aug;6(8):613-24. (PMID: 18628769)
Antiviral Res. 2015 Mar;115:21-38. (PMID: 25554382)
Annu Rev Biochem. 2012;81:203-29. (PMID: 22524316)
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22. (PMID: 16581910)
Science. 2003 Dec 12;302(5652):1972-5. (PMID: 14671306)
Curr Top Microbiol Immunol. 2005;287:1-30. (PMID: 15609507)
EMBO J. 2007 Jul 11;26(13):3062-74. (PMID: 17568776)
J Gen Virol. 2000 Apr;81(Pt 4):853-79. (PMID: 10725411)
Nat Rev Mol Cell Biol. 2009 Aug;10(8):550-63. (PMID: 19626045)
Biochem Biophys Res Commun. 2004 Nov 12;324(2):579-83. (PMID: 15474466)
Virology. 1995 Apr 1;208(1):1-8. (PMID: 11831690)
FEBS Lett. 1997 Dec 22;420(1):25-7. (PMID: 9450543)
FEBS Lett. 2004 Sep 10;574(1-3):131-7. (PMID: 15358553)
Biochem Biophys Res Commun. 2007 Dec 28;364(4):877-82. (PMID: 17976532)
Annu Rev Biochem. 2001;70:503-33. (PMID: 11395416)
J Virol. 2014 Nov;88(21):12511-27. (PMID: 25142582)
Virology. 2015 May;479-480:52-65. (PMID: 25753787)
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):12997-13002. (PMID: 27799534)
Aging Dis. 2020 Mar 9;11(2):216-228. (PMID: 32257537)
Cell. 2009 Mar 20;136(6):1098-109. (PMID: 19303852)
Arch Biochem Biophys. 2007 Oct 1;466(1):8-14. (PMID: 17692280)
Protein Cell. 2014 May;5(5):369-81. (PMID: 24622840)
J Biol Chem. 2015 Jan 30;290(5):3172-82. (PMID: 25505178)
Cell Cycle. 2013 Sep 1;12(17):2733-7. (PMID: 23966173)
J Innate Immun. 2020;12(1):4-20. (PMID: 31610541)
J Biol Chem. 2001 Aug 31;276(35):33220-32. (PMID: 11431476)
J Virol. 2008 Jun;82(11):5279-94. (PMID: 18367524)
J Gen Virol. 2003 Sep;84(Pt 9):2305-2315. (PMID: 12917450)
Nature. 1995 Jan 5;373(6509):81-3. (PMID: 7800044)
Sci Rep. 2017 Jan 12;7:40292. (PMID: 28079137)
J Virol. 2005 Dec;79(24):15189-98. (PMID: 16306590)
Annu Rev Immunol. 2004;22:81-127. (PMID: 15032575)
J Virol. 2009 Jul;83(13):6689-705. (PMID: 19369340)
Cell. 2003 Mar 21;112(6):779-91. (PMID: 12654245)
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E838-47. (PMID: 23401522)
J Virol. 2020 May 18;94(11):. (PMID: 32188729)
J Biol Chem. 2005 Sep 2;280(35):31257-66. (PMID: 15788388)
PLoS Pathog. 2009 Jul;5(7):e1000530. (PMID: 19649319)
Nucleic Acids Res. 1990 Apr 11;18(7):1825-32. (PMID: 2159623)
Adv Exp Med Biol. 2006;581:37-41. (PMID: 17037501)
Antiviral Res. 2018 Feb;150:155-163. (PMID: 29289665)
Rev Med Virol. 2013 Jul;23(4):213-20. (PMID: 23255396)
Nature. 1997 May 15;387(6630):296-9. (PMID: 9153395)
Microbiol Mol Biol Rev. 2006 Dec;70(4):939-1031. (PMID: 17158705)
Virus Res. 2014 Dec 19;194:184-90. (PMID: 24512893)
PLoS One. 2012;7(2):e30802. (PMID: 22312431)
Cytokine Growth Factor Rev. 2014 Dec;25(6):707-13. (PMID: 25001414)
Grant Information:
AB17190534 International Key Project of Guangxi Scienticfic Research and Tecknology Development Plan; 31560315 International National Natural Science Foundation of China (NSFC)
Contributed Indexing:
Keywords: ISG15; PLpro; SARS-CoV; SARS-CoV-2; p53; ubiquitin
Substance Nomenclature:
0 (NF-kappa B)
0 (Viral Proteins)
EC 2.3.2.23 (Ubiquitin-Conjugating Enzymes)
EC 2.3.2.27 (Ubiquitin-Protein Ligases)
EC 3.4.22.2 (Coronavirus Papain-Like Proteases)
EC 3.4.22.2 (papain-like protease, SARS coronavirus)
EC 3.4.22.2 (papain-like protease, SARS-CoV-2)
EC 6.2.1.45 (Ubiquitin-Activating Enzymes)
Entry Date(s):
Date Created: 20201228 Date Completed: 20210111 Latest Revision: 20221207
Update Code:
20240105
PubMed Central ID:
PMC7883198
DOI:
10.1096/fj.202002271
PMID:
33368679
Czasopismo naukowe
SARS-CoV and SARS-CoV-2 encode four structural and accessory proteins (spike, envelope, membrane and nucleocapsid proteins) and two polyproteins (pp1a and pp1ab). The polyproteins are further cleaved by 3C-like cysteine protease (3CL pro ) and papain-like protease (PL pro ) into 16 nonstructural proteins (nsps). PL pro is released from nsp3 through autocleavage, and then it cleaves the sites between nsp1/2, between nsp2/3 and between nsp3/4 with recognition motif of LXGG, and the sites in the C-terminus of ubiquitin and of protein interferon-stimulated gene 15 (ISG15) with recognition motif of RLRGG. Alone or together with SARS unique domain (SUD), PL pro can stabilize an E3 ubiquitin ligase, the ring-finger, and CHY zinc-finger domain-containing 1 (RCHY1), through domain interaction, and thus, promote RCHY1 to ubiquitinate its target proteins including p53. However, a dilemma appears in terms of PL pro roles. On the one hand, the ubiquitination of p53 is good for SARS-CoV because the ubiquitinated p53 cannot inhibit SARS-CoV replication. On the other hand, the ubiquitination of NF-κB inhibitor (IκBα), TNF receptor-associated factors (TRAFs), and stimulator of interferon gene (STING), and the ISGylation of targeted proteins are bad for SARS-CoV because these ubiquitination and ISGylation initiate the innate immune response and antiviral state. This mini-review analyzes the dilemma and provides a snapshot on how the viral PL pro smartly manages its roles to avoid its simultaneously contradictory actions, which could shed lights on possible strategies to deal with SARS-CoV-2 infections.
(© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies